Adalimumab
- Generic Name
- Adalimumab
- Brand Names
- Amjevita, Cyltezo, Humira, Hyrimoz, Yusimry, Hulio, Hefiya, Libmyris, Imraldi, Amsparity, Idacio, Hukyndra, Amgevita, Yuflyma
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 331731-18-1
- Unique Ingredient Identifier
- FYS6T7F842
- Background
Adalimumab is a subcutaneously administered biological disease modifier for the treatment of rheumatoid arthritis and other chronic debilitating diseases mediated by tumor necrosis factor. It was originally launched by Abbvie in the U.S. and approved in 2002 by the FDA. This drug is frequently known as Humira. It is produced by recombinant DNA technology usi...
- Indication
Adalimumab is indicated for the following conditions:
Adalimumab has also been used off-label to treat Pyoderma gangrenosum.
- Associated Conditions
- Ankylosing Spondylitis (AS), Hidradenitis Suppurativa (HS), Moderate to Severe Chronic Plaque Psoriasis, Moderate to Severe Rheumatoid Arthritis, Moderately to Severely Active Crohn's Disease, Moderately to Severely Active Ulcerative Colitis, Non-infectious Intermediate, Posterior and Panuveitis, Polyarticular Juvenile Idiopathic Arthritis, Psoriatic Arthritis, Pyoderma Gangrenosum
- Associated Therapies
- -
Multicenter Randomized Prospective Trial Comparing Methotrexate Alone or in Combination With Adalimumab in Early Arthritis
- Conditions
- First Posted Date
- 2006-02-15
- Last Posted Date
- 2006-02-15
- Target Recruit Count
- 80
- Registration Number
- NCT00291915
- Locations
- 🇫🇷
Hopital Cochin, Paris, France
A Study of Adalimumab to Treat Sarcoidosis of the Skin
- Conditions
- First Posted Date
- 2006-01-10
- Last Posted Date
- 2013-05-22
- Lead Sponsor
- Pariser, Robert J., M.D.
- Target Recruit Count
- 16
- Registration Number
- NCT00274352
- Locations
- 🇺🇸
Virginia Clinical Research, Inc., Norfolk, Virginia, United States
Efficacy and Safety of Adalimumab in Subjects With Moderate to Severe Chronic Plaque Psoriasis
- Conditions
- First Posted Date
- 2005-10-13
- Last Posted Date
- 2007-08-29
- Lead Sponsor
- Abbott
- Target Recruit Count
- 1212
- Registration Number
- NCT00237887
Adalimumab Administered in Korean Rheumatoid Arthritis Subjects Treated With Methotrexate
- Conditions
- First Posted Date
- 2005-10-12
- Last Posted Date
- 2007-08-29
- Lead Sponsor
- Abbott
- Target Recruit Count
- 128
- Registration Number
- NCT00235859
Safety and Efficacy Study of Adalimumab in Patients With Active Psoriatic Arthritis (PsA)
- Conditions
- First Posted Date
- 2005-10-12
- Last Posted Date
- 2007-08-29
- Lead Sponsor
- Abbott
- Target Recruit Count
- 445
- Registration Number
- NCT00235885
- Locations
- 🇺🇸
Global Medical Information - Abbott, Abbott Park, Illinois, United States
Safety and Efficacy of Adalimumab to Methotrexate and Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis
- Conditions
- Interventions
- First Posted Date
- 2005-10-12
- Last Posted Date
- 2008-07-17
- Lead Sponsor
- Abbott
- Target Recruit Count
- 271
- Registration Number
- NCT00235820
- Locations
- 🇺🇸
Global Medical Information-Abbott, Abbott Park, Illinois, United States
Adalimumab in Combination With Methotrexate vs Methotrexate Alone in Early Rheumatoid Arthritis
- Conditions
- First Posted Date
- 2005-10-10
- Last Posted Date
- 2007-08-29
- Lead Sponsor
- Abbott
- Target Recruit Count
- 148
- Registration Number
- NCT00234845
- Locations
- 🇺🇸
Global Medical Information - Abbott, Abbott Park, Illinois, United States
Quality of Life Study With Adalimumab in Rheumatoid Arthritis
- Conditions
- First Posted Date
- 2005-10-10
- Last Posted Date
- 2007-10-03
- Lead Sponsor
- Abbott
- Target Recruit Count
- 200
- Registration Number
- NCT00234936
Efficacy of HUMIRA in Subjects With Active Rheumatoid Arthritis
- Conditions
- First Posted Date
- 2005-10-10
- Last Posted Date
- 2007-08-29
- Lead Sponsor
- Abbott
- Target Recruit Count
- 1938
- Registration Number
- NCT00234897
- Locations
- 🇺🇸
Global Medical Information - Abbott, North Chicago, Illinois, United States
Predictors of the Response to Adalimumab in Rheumatoid Arthritis
- Conditions
- First Posted Date
- 2005-10-06
- Last Posted Date
- 2012-02-09
- Lead Sponsor
- University Hospital, Rouen
- Target Recruit Count
- 200
- Registration Number
- NCT00234234
- Locations
- 🇫🇷
MARCELLI, Caen, Basse Normandie, France
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.